Dr. Hayato Urabe is Senior Director of Investment Strategy, Portfolio Development and Innovations at the Global Health Innovative Technology (GHIT) Fund. Dr. Urabe is responsible for driving the development of $300M+ investment strategy for product development (drugs, vaccines, and diagnostics) for malaria, tuberculosis, and Neglected Tropical Diseases. He directs investment strategy of GHIT’s investments with 100+ global health R&D partnerships around the world.
Prior to joining the GHIT Fund, Dr. Urabe held several positions across the energy, life sciences, and high-tech sectors focusing on strategy planning, global market analysis, business expansion and growth strategy development in the Silicon Valley. Dr. Urabe completed his Doctor of Philosophy in Biomedical engineering from Brown University and received Master of Pacific International Affairs from the School of Global Policy & Strategy at University of California, San Diego.